Detecting contaminants
Cambrex Bio Science has signed an exclusive licence agreement with The Johns Hopkins University, of Maryland, for access to two novel, quantitative assay technologies for the detection of contaminants in drugs, beverages and food.
The technologies will be used to develop products and services for use in microbial testing of drugs, vaccines, biopharmaceuticals, cell therapeutics, nutraceuticals, cosmetics and food. 'This licence extends our capabilities to identify and quantify pathogens utilising the recently licensed Epoch MGB Eclipse technology and the recently acquired Genolife know-how,' said Dave Eansor, president, Cambrex Bioproducts. 'We will leverage our success and experience with endotoxin and mycoplasma detection testing to establish a market-leading position in the drug, food and personal care markets.'